---
document_datetime: 2025-05-06 11:23:39
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mayzent-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: mayzent-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 6.4490745
conversion_datetime: 2025-12-28 04:26:07.576608
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mayzent

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0032              | Update of sections 5.1 and 4.8 of the SmPC in order to update efficacy and safety information from study CBAF312A2304 (EXPAND) listed as a category 3 study in the RMP. This is a phase III study and is comprised of two parts: a Core Part and an Extension Part. The Core Part was a multicenter, | 27/03/2025                          |                                             | SmPC                             | Section 4.8 of the SmPC has been updated to inform that the safety-related information from the open-label extension part of the study A2304 (EXPAND) was consistent with that observed in the core part. Section 5.1 of the SmPC has been updated to inform about the percentage of patients who enrolled the open-label |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of siponimod in SPMS patients. This was followed by an open-label Extension Part, collecting long-term efficacy and safety data on siponimod for up to 7 years. In addition, the MAH took the opportunity to add editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                  | extension part of the study A2304 (EXPAND) and developed 6-month CDP at month 108. These exploratory results were presented for separately for patients initially allocated to siponimod in the core part of the study and for those who switched from placebo to siponimod after the core part. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10818 /202403 | Periodic Safety Update EU Single assessment - siponimod                                                                                                                                                                                                                                                                                                                                                                                                 | 14/11/2024 | 13/01/2025 | SmPC, Annex II and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10818/202403.                                                                                                                                                                                                                                       |
| IAIN/0033           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                  | 16/12/2024 |            | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0029              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                 | 25/07/2024 | 19/09/2024 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety, and efficacy, the CHMP considered that the benefit-risk balance of Mayzent in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                           |
| IA/0030             | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                           | 13/05/2024 | 19/09/2024 | SmPC                             |                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0028/G         | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                      | 26/02/2024 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.7 - Administrative change - Deletion of   |            |            |             |                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10818 /202303 | Periodic Safety Update EU Single assessment - siponimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/11/2023 | 05/01/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                            |            |            |      | PSUSA/10818/202303.                                                                                                                                                                                                                                                                                |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0027 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                         | 22/12/2023 | n/a        |      |                                                                                                                                                                                                                                                                                                    |
| IB/0026/G | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.z - Change in control of the Finished Product - Other variation                                                                                                             | 13/12/2023 | n/a        |      |                                                                                                                                                                                                                                                                                                    |
| II/0023   | Update of section 5.1 of the SmPC in order to present data on the effect of siponimod on delaying the progression to EDSS ≥7 (time -to-wheelchair) based on post-hoc analysis of study CBAF312A2304 (EXPAND). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data            | 30/11/2023 | 19/09/2024 | SmPC | Section 5.1 of the SmPC has been updated in order to present data on the effect of siponimod on delaying the progression to EDSS ≥7 (time -to-wheelchair) based on post-hoc analysis of study CBAF312A2304 (EXPAND). For more information, please refer to the Summary of Product Characteristics. |
| IA/0025/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release | 07/09/2023 | n/a        |      |                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or                                                                                                                               | 25/08/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0020   | Update of sections 4.4 and 4.8 of the SmPC in order to add 'Progressive multifocal leukoencephalopathy (PML)' to the list of adverse drug reactions (ADRs) with frequency 'not know' based on post-marketing data. The Annex II (Physician's Checklist), and Package Leaflet are updated accordingly. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the text regarding herpes viral infection in the Package Leaflet in alignment with the currently approved SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 06/07/2023 | 05/01/2024 | SmPC and PL | Update of sections 4.4 and 4.8 of the SmPC in order to add 'Progressive multifocal leukoencephalopathy (PML)' to the list of adverse drug reactions (ADRs) with frequency 'not know' based on post-marketing data. The Annex II (Physician's Checklist), and Package Leaflet are updated accordingly. The RMP version 6.0 has also been submitted. In addition, the MAH took the opportunity to update the text regarding herpes viral infection in the Package Leaflet in alignment with the currently approved SmPC. The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IB/0021             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                | 05/04/2023   | n/a        |                       |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10818 /202203 | Periodic Safety Update EU Single assessment - siponimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 10/11/2022   | 12/01/2023 | SmPC and PL           | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10818/202203. |
| PSUSA/10818 /202109 | Periodic Safety Update EU Single assessment - siponimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 19/05/2022   | 18/07/2022 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10818/202109. |
| IG/1521             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/06/2022   | n/a        |                       |                                                                                                                                            |
| IA/0016/G           | This was an application for a group of variations. B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch | 01/06/2022   | n/a        |                       |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        |                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------|
| IB/0015/G | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 08/03/2022 | n/a        |                        |                                                      |
| X/0007    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 16/12/2021 | 16/02/2022 | SmPC, Labelling and PL |                                                      |
| II/0011/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 11/11/2021 | 16/02/2022 | SmPC                   | For more information, please refer to the Summary of |

<div style=\"page-break-after: always\"></div>

|                     | Update of section 4.5 of the SmPC to clarify the CYP2C9/CYP3A4 inhibitors/inducers information. Update of section 5.2 to add information regarding CYP2C9 genotypes less frequent alleles. Update of sections 4.4 and 4.5 of the SmPC to add information in case of administration of non-live attenuated vaccines, based on the vaccination study A2130. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   |            |            |                 | Product Characteristics.          |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/10818 /202103 | Periodic Safety Update EU Single assessment - siponimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 28/10/2021 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0013/G         | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information A.5.b - Administrative change - Change in the name                                                                                                                              | 06/10/2021 | 16/02/2022 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0012             | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 06/08/2021 | n/a |                                   |
| IB/0009/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 13/07/2021 | n/a |                                   |
| PSUSA/10818 /202009 | Periodic Safety Update EU Single assessment - siponimod                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/04/2021 | n/a | PRAC Recommendation - maintenance |
| IA/0006/G           | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/01/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                          |            |            |                        |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10818 /202003 | Periodic Safety Update EU Single assessment - siponimod                                                                                                                                                                                                                                                                                                                                                                                                    | 12/11/2020 | 07/01/2021 | SmPC, Annex II and PL  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10818/202003. |
| IAIN/0004           | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                                                                                                                                                                      | 21/08/2020 | 07/01/2021 | Annex II and PL        |                                                                                                                                            |
| IB/0002/G           | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes | 02/04/2020 | 07/01/2021 | SmPC, Labelling and PL |                                                                                                                                            |
| IAIN/0001           | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                         | 17/02/2020 | 07/01/2021 | SmPC, Labelling and PL |                                                                                                                                            |